Role of Montelukast in Asthma and Allergic Rhinitis Patients
Launched by CLINISION · Dec 18, 2017
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
Montelukast is a potent and selective blocker of the CysLT1 receptor. Accordingly, a recent study has shown that Montelukast can improve symptoms of seasonal allergic rhinitis and asthma in patients with both diseases. For treatment of asthma, Montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form. Asthma and allergic rhinitis have been linked clinically for many years as "one airway one diseases". Patients with allergic asthma and rhinitis are signif...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • Signed Informed Consent
- • Clinical diagnosis of Asthma and Allergic Rhinitis
- Exclusion Criteria:
- • Previous adverse reaction to Montelukast
- • History of hyper-eosinophilic disorder other than atopic disease
- • Female subjects who are pregnant, breast-feeding
- • Any significant and active pulmonary pathology other than asthma
About Clinision
Clinision is a leading clinical trial sponsor dedicated to advancing medical research through innovative study design and execution. With a commitment to enhancing patient outcomes, Clinision partners with healthcare providers and research organizations to facilitate the development of new therapies across various therapeutic areas. Their expertise encompasses all phases of clinical trials, ensuring rigorous adherence to regulatory standards and ethical considerations. By leveraging cutting-edge technology and a patient-centered approach, Clinision aims to streamline the trial process, optimize data integrity, and ultimately bring transformative treatments to market efficiently and effectively.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Faisal Faiyaz, FCPS,FCPS
Principal Investigator
Dow University of Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials